# Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP  
---|---  
dc.contributor.author |  VERHOEF, Gregor  
ROBAK, Tadeusz  
HUANG, Huiqiang  
PYLYPENKO, Halyna  
SIRITANARATKUL, Noppadol  
PEREIRA, Juliana    
DRACH, Johannes  
MAYER, Jiri  
OKAMOTO, Rumiko  
PEI, Lixia  
ROONEY, Brendan  
CAKANA, Andrew  
VELDE, Helgi van de  
CAVALLI, Franco  
  
dc.date.issued | 2017  
dc.identifier.citation | HAEMATOLOGICA, v.102, n.5, p.895-902, 2017  
dc.identifier.issn | 0390-6078  
dc.identifier.uri |  http://observatorio.fm.usp.br/handle/OPI/21232  
dc.description.abstract | In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7 versus 14.4 months with R-CHOP; P<0.001). This post-hoc analysis evaluated the association between the improved outcomes and quality of responses achieved with VR-CAP versus R-CHOP in LYM-3002. Patients were randomized to six to eight 21-day cycles of VR-CAP or R-CHOP. Outcomes included progression-free survival, duration of response (both assessed by an independent review committee), and time to next anti-lymphoma treatment, evaluated by response (complete response/unconfirmed complete response and partial response), MIPI risk status, and maximum reduction of lymph-node measurements expressed as the sum of the product of the diameters. Within each response category, the median progression-free survival was longer for patients given VR-CAP than for those given R-CHOP (complete response/unconfirmed complete response: 40.9 versus 19.8 months; partial response: 17.1 versus 11.7 months, respectively); similarly, the median time to next anti-lymphoma treatment was longer among the patients given VR-CAP than among those treated with R-CHOP (complete response/unconfirmed complete response: not evaluable versus 26.6 months; partial response: 35.3 versus 24.3 months). Within the complete/unconfirmed complete and partial response categories, improvements in progression-free survival, duration of response and time to next anti-lymphoma treatment were more pronounced in patients with low- and intermediate-risk MIPI treated with VR-CAP than with R-CHOP. In each response category, more VR-CAP than R-CHOP patients had a sum of the product of the diameters nadir of 0 during serial radiological assessments. Results of this post-hoc analysis suggest a greater duration and quality of response in patients treated with VR-CAP in comparison with those treated with R-CHOP, with the improvements being more evident in patients with low-and intermediate-risk MIPI. LYM-3002 ClinicalTrials.gov: NCT00722137.  
dc.description.sponsorship |  · Millennium Pharmaceuticals, Inc.  
· Janssen Global Services, LLC.  
  
dc.language.iso | eng  
dc.publisher | FERRATA STORTI FOUNDATION  
dc.relation.ispartof | Haematologica  
dc.rights | openAccess  
dc.subject.other | prognostic index; guidelines; rituximab; survival; criteria; therapy; network  
dc.title | Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study  
dc.type | article  
dc.rights.holder | Copyright FERRATA STORTI FOUNDATION  
dc.description.group | LIM/31  
dc.identifier.doi |  10.3324/haematol.2016.152496  
dc.identifier.pmid |  28183846  
dc.type.category | original article  
dc.type.version | publishedVersion  
hcfmusp.author | PEREIRA, Juliana:FM:MCM  
  
hcfmusp.author.external |  · VERHOEF, Gregor:Univ Hosp Leuven, Leuven, Belgium  
· ROBAK, Tadeusz:Med Univ Lodz, Copernicus Mem Hosp, Lodz, Poland  
· HUANG, Huiqiang:Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China  
· PYLYPENKO, Halyna:Cherkassy Reg Oncol Ctr, Cherkassy, Ukraine  
· SIRITANARATKUL, Noppadol:Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok, Thailand  
· DRACH, Johannes:Univ Vienna, Vienna Gen Hosp, Vienna, Austria  
· MAYER, Jiri:Masaryk Univ Hosp Brno, Brno, Czech Republic  
· OKAMOTO, Rumiko:Chibanishi Gen Hosp, Chiba, Japan; Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan  
· PEI, Lixia:Janssen Res & Dev LLC, Raritan, NJ USA  
· ROONEY, Brendan:Janssen Res & Dev, High Wycombe, Bucks, England  
· CAKANA, Andrew:Janssen Res & Dev, High Wycombe, Bucks, England  
· VELDE, Helgi van de:Millennium Pharmaceut Inc, Boston, MA USA  
· CAVALLI, Franco:Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland, Bellinzona, Ticino, Switzerland  
  
hcfmusp.origem.id |  WOS:000402490900026  
hcfmusp.origem.id |  2-s2.0-85018971634  
hcfmusp.publisher.city | PAVIA  
hcfmusp.publisher.country | ITALY  
hcfmusp.relation.reference |  · Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403   
· Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800   
· Dreyling M, 2013, ANN ONCOL, V24, P857, DOI 10.1093/annonc/mds643   
· Dreyling M, 2015, NAT REV CLIN ONCOL, V12, P377, DOI 10.1038/nrclinonc.2015.101   
· Frosch Z, 2015, CL LYMPH MYELOM LEUK, V15, P92, DOI 10.1016/j.clml.2014.07.017   
· Hoster E, 2008, BLOOD, V111, P558, DOI 10.1182/blood-2007-06-095331   
· Hoster E, 2014, J CLIN ONCOL, V32, P1338, DOI 10.1200/JCO.2013.52.2466   
· Howard OM, 2002, J CLIN ONCOL, V20, P1288, DOI 10.1200/JCO.20.5.1288   
· Howlader N, 2015, SEER CANC STAT REV 1  
· Juweid ME, 2005, J CLIN ONCOL, V23, P4652, DOI 10.1200/JCO.2005.01.891   
· McKay P, 2012, BRIT J HAEMATOL, V159, P405, DOI 10.1111/bjh.12046   
· Millennium Pharmaceuticals Inc, 2014, VELCADE BORT INJ SUB  
· Pott C, 2010, BLOOD, V115, P3215, DOI 10.1182/blood-2009-06-230250   
· Robak T, 2015, NEW ENGL J MED, V372, P944, DOI 10.1056/NEJMoa1412096   
· Rummel MJ, 2013, LANCET, V381, P1203, DOI 10.1016/S0140-6736(12)61763-2   
· Smith A, 2015, BRIT J CANCER, V112, P1575, DOI 10.1038/bjc.2015.94   
· Zhou YH, 2008, CANCER, V113, P791, DOI 10.1002/cncr.23608   
  
dc.description.index | MEDLINE  
hcfmusp.citation.scopus | 1  
hcfmusp.citation.wos | 0  
hcfmusp.affiliation.country | Brasil  
hcfmusp.affiliation.country | Ucrânia  
hcfmusp.affiliation.country | Tailândia  
hcfmusp.affiliation.country | Áustria  
hcfmusp.affiliation.country | República Tcheca  
hcfmusp.affiliation.country | Japão  
hcfmusp.affiliation.country | Estados Unidos  
hcfmusp.affiliation.country | Bélgica  
hcfmusp.affiliation.country | Inglaterra  
hcfmusp.affiliation.country | Suíça  
hcfmusp.affiliation.country | China  
hcfmusp.affiliation.country | Polônia  
  
## Files in this item

Name: art_VERHOEF_Association_between_quality_of_respons ...

Size: 1.798Mb

Format: PDF

Description: publishedVersion (English)